

MRES: M2Bio Sciences Marks Milestone Expansion with Launch of Los Angeles Office

CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, November 14, 2023 /EINPresswire.com/ -- Institute of Biomedical Research Corp. (OTC PINK: MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update:

M2Bio Sciences Food & Beverage strategically expands its presence by opening offices in Los Angeles, California. This move aims to broaden the distribution of [Liviana™](#) and [Medspresso™](#) products within the United States, aligning with the company's global commitment to providing healthy and trusted food products backed by evidence-based clinical science.

M2Bio is set to collaborate with Rand Capital Coffee within the premises. Rand Capital, founded in 2010, oversees and manages over 70 premium coffee cafes across Southern Africa. The offices are at 1515 Palisades Drive, Pacific Palisades, CA.

Michael Sachar, CEO of M2Bio Sciences Food and Beverage, expressed excitement about the expansion, stating, "We are ecstatic about opening the M2Bio Sciences Food and Beverage offices in Los Angeles. Having a solid base in California allows us to gain a foothold on the West Coast as our rollout for North American distribution for 2024 gains momentum. We have seen



LIVIANA

phenomenal growth in the food division and are excited to share our premium health-centric products with new partners and consumers."

About Institute of Biomedical Research Corp./ DBA M2Bio Sciences

Institute of Biomedical Research Corp is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as artificial intelligence-powered nutrition products and solutions under the M2Biome brand. In addition, our research and clinical trials with psilocybin are aimed at new therapies to help patients suffering from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence.

The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES."

Publicly traded Company (OTC Pink: MRES)

www.m2bio.co

Forward-Looking Statements

Safe Harbour Statement - Besides historical information, this press release may contain forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team concerning the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance, involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments concerning litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

CONTACT:

Jeff Robinson
M2Bio Sciences

+27 72 333 2148

[Email us here](#)

Jeff Robinson

M2Bio Sciences Food and Beverage (Pty) Ltd

+27 72 333 2148

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/668382856>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.